Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00113048
Status:
TERMINATED
Last Update Posted:
2014-02-05
First Post:
2005-06-03
Brief Title:
Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Hematologic Malignancies |
Keywords:
| Name | View |
|---|---|
| CD52 Expressing Hematologic Malignancies | View |